Evidence used to support decisions must be broad-based. Regional immunization policy decisions have historically relied primarily on the burden of disease and vaccine efficacy; however, the higher cost of new vaccines will require a much broader evidence base ranging from cost effectiveness and financial sustainability to health systems concerns.